pT3N0M0期胸段食管鳞癌术后辅助性治疗对预后影响的初步分析

doi:10.3760/cma.j.issn.1004-4221.2017.08.005

摘要
图/表
参考文献()
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (844 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的探讨pT₃N₀M₀期胸段食管鳞癌(TSCC)术后患者预后影响因素,同时比较不同治疗模式对预后影响。方法对2007—2010年间收治的 480例pT₃N₀M₀期TSCC术后患者进行回顾分析,分析其预后影响因素,同时比较不同治疗模式对预后影响。Kaplan-Meier法计算生存率,Cox模型多因素预后分析。结果全组患者随访满1、3、5年者分别为439、333、278例,1、3、5年OS和DFS分别为90.0%、68.7%、57.9%和82.3%、60.4%、52.3%,中位数分别为87个月(95%CI=74.7~99.4)和71.3个月(95%CI=55.1~87.5)。三组患者部分临床病理资料的构成比有差异,经倾向得分匹配法法配对后每组各 55例患者且各组具有可比性(P均>0.05),倾向得分匹配法配对后单纯手术、术后化疗、术后放化疗/放疗患者的1、3、5年OS和DFS差异均有统计学意义(P=0.000、0.006);Cox多因素分析结果显示患者年龄、病变部位和治疗方式为影响患者OS和DFS的因素(P=0.029、0.004、0.000,P=0.009、0.003、0.002),另外病变长度为影响患者DFS的因素(P=0.003)。结论 pT₃N₀M₀期TSCC术后患者仍有较高的治疗失败率,术后放化疗或放疗可以改善pT₃N₀M₀期TSCC患者的预后,提高术后患者 5年OS和DFS,但最终结论需要前瞻性大宗病例的进一步证实。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	沈文斌
	高红梅
	祝淑钗
	李腾
	李曙光
	李幼梅
	刘志坤
	李娟
	苏景伟

关键词 ：食管肿瘤/外科学, 食管肿瘤/术后放疗, 食管肿瘤/术后化疗, 预后

Abstract： Objective To determine the prognostic factors in patients with stage pT₃N₀M₀ thoracic esophageal squamous cell carcinoma (TSCC) after esophagectomy, and to compare the effects of different treatment modalities on the prognosis of patients. Methods A retrospective analysis was conducted on 480 patients with stage pT₃N₀M₀ TSCC from 2007 to 2010 to determine the prognostic factors in the patients, and to compare the effects of different treatment modalities on their prognosis. Survival rate was calculated using the Kaplan-Meier estimator, and multivariate analysis of prognostic factors was performed using the Cox model. Results Of the 439, 333, and 278 patients who completed the 1-, 3-, and 5-year follow-up, respectively, the 1-, 3-, and 5-year overall survival (OS) rates were 90.0%, 68.7%, and 57.9%(median 87 months, 95% confidence interval (CI=74.7-99.4), respectively, and the 1-, 3-, and 5-year disease-free survival (DFS) rates were 82.3%, 60.4%, and 52.3%(median 71.3 months, 95%CI=55.1-87.5), respectively. In order to account for the different constituent ratios of some clinical and pathological data between the three groups of patients, 55 patients in each group were matched using propensity score matching (PSM)(all P>0.05). It was found that the post-PSM 1-,3-, and 5-year OS and DFS were significantly different between patients who received surgery only, postoperative chemotherapy (POCT), and postoperative chemoradiotherapy/radiotherapy (POCRT/RT)(P=0.000 and 0.006,respectively). Multivariate Cox analysis showed that age, lesion location, and treatment modality were independent prognostic factors for OS and DFS (P=0.029,0.004,0.000 and P=0.009,0.003,0.002), and the length of lesion was also an independent prognostic factor for DFS (P=0.003). Conclusions Although the rate of post-operative treatment failure is still high among patients with stage pT₃N₀M₀ TSCC, POCRT/PORT can improve the prognosis and the 5-year OS and DFS of these patients. However, further large-sample prospective studies will be required to confirm these findings.

Key words： Esophageal neoplasms/surgery Esophageal neoplasms/postoperative radiotherapy Esophageal neoplasms/postoperative chemotherapy Prognosis

收稿日期: 2016-11-14

通讯作者: 祝淑钗,Email:sczhu1965@163.com

引用本文:

沈文斌,高红梅,祝淑钗等. pT₃N₀M₀期胸段食管鳞癌术后辅助性治疗对预后影响的初步分析[J]. 中华放射肿瘤学杂志, 2017, 26(8): 867-873.

Shen Wenbin,Gao Hongmei,Zhu Shuchai et al. Effect of postoperative adjuvant therapy on the prognosis of patients with stage pT₃N₀M₀ thoracic esophageal squamous cell carcinoma:a preliminary analysis[J]. Chinese Journal of Radiation Oncology, 2017, 26(8): 867-873.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.issn.1004-4221.2017.08.005 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2017/V26/I8/867

[1] Xiao ZF,Yang ZY,Liang J,et al. Value of radiotherapy after radical surgery for esophageal carcinoma:a reportof 495 patients[J].Ann Thorac Surg,2003,75(2):331-336.DOI:10.1016/S0003-4975(02)04401-6.
[2] 杨劲松,章文成,肖泽芬,等.术后辅助3DRT改善pT₃N₀M₀期食管癌患者长期生存[J].中华放射肿瘤学杂志,2015,24(2):101-105.DOI:10.3760/cma.j.issn.1004-4221.2015.02.sss.
Yang JS,Zhang WC,Xiao ZF,et al. Postoperative adjuvant three-dimensional conformal radiotherapy improves long-term survival in patients with pathological T_2-3N₀M₀ esophageal cancer[J].Chin J Radiat Oncol,2015,24(2):101-105.DOI:10.3760/cma.j.issn.1004-4221.2015.02.sss.
[3] Wang YX,Wang LL,Yang Q,et al. Factors on prognosis in patients of stage pT₃N₀M₀ thoracic esophageal squamous cell carcinoma after two-field esophagectomy[J].J Cancer Res Ther,2015,11(5):16-23.DOI:10.4103/0973-1482.163833.
[4] 刘晓,章文成,于舒飞,等.T_2-3N₀M₀期食管癌R₀术后失败模式分析——术后放疗潜在价值与意义[J].中华放射肿瘤学杂志,2015,24(1):19-24.DOI:10.3760/cma.j.issn.1004-4221.2015.01.006.
Liu X,Zhang WC,Yu SF,et al. Patterns of failure after radical surgery among patients with stage T_2-3N₀M₀ esophageal squamous cell carcinoma——potential value of postoperative radiotherapy[J].Chin J Radiat Oncol,2015,24(1):19-24.DOI:10.3760/cma.j.issn.1004-4221.2015.01.006.
[5] Worni M,Martin J,Gloor B,et al. Does surgery improveoutcomes for esophageal squamous cell carcinoma?An analysisusing the surveillance epidemiology and end results registry from1998 to 2008[J].J Am Coll Surg,2012,215(5):643-651.DOI:10.1016/j.jamcollsurg.2012.07.006.
[6] Visbal AL,Allen MS,Miller DL,et al. Ivor lewisesophagogastrectomy for esophageal cancer[J].AnnThorac Surg,2001,71(6):1803-1808.DOI:10.1016/S0003-4975(01)02601-7.
[7] Ando N,Iizuka T,Ide H,et al. Surgery plus chemotherapycompared with surgery alone for localized squamous cell carcinomaof the thoracic esophagus:a Japan clinical oncology group study-JCOG9204[J].J Clin Oncol,2003,21(24):4592-4596.DOI:10.1200/JCO.2003.12.095.
[8] Hsu PK,Wang BY,Huang CS,et al. Prognostic factors for post-recurrence survival in esophageal squamous cell carcinoma patients with recurrence after resection[J].J Gastrointest Surg,2011,15(4):558-565.DOI:10.1007/s11605-011-1458-1.
[9] 张冬坤,苏晓东,林鹏,等.467例Ⅱ期胸段食管鳞癌切除术后患者的生存分析[J].癌症,2008,27(2):113-118.DOI:10.3321/j.issn:1000-467X.2008.02.001.
Zhang DK,Su XD,Lin P,et al. Survival analysis of patients with stage Ⅱsquamous cell carcinoma of the thoracic esophagus after esophagectomy[J].Chin J Cancer,2008,27(2):113-118.DOI:10.3321/j.issn:1000-467X.2008.02.001.
[10] Shridhar R,Weber J,Hoffe SE,et al. Adjuvant radiation therapy and lymphadenectomy in esophageal cancer:a SEER database analysis[J].J Gastrointest Surg,2013,17(8):1339-1345.DOI:10.1007/s11605-013-2192-7.
[11] 杨劲松,刘晓,肖泽芬,等.pT_2-3N₀M₀期食管癌根治术后3DRT前瞻性Ⅱ期临床研究[J].中华放射肿瘤学杂志,2015,24(1):29-32.DOI:10.3760/cma.j.issn.1004-4221.2015.01.008.
Yang JS,Liu X,Xiao ZF,et al. Prospective phase Ⅱ study of three-dimensional radiotherapy after radical surgery for pT_2-3N₀M₀ esophageal cancer[J].Chin J Radiat Oncol,2015,24(1):29-32.DOI:10.3760/cma.j.issn.1004-4221.2015.01.008.
[12] Martin JT,Worni M,Zwischenberger JB,et al. The role of radiation therapy in resected T₂N₀ esophageal cancer:a population-based analysis[J].Ann Thorac Surg,2013,95(2):453-458.DOI:10.1016/j.athoracsur.2012.08.049.
[13] Schreiber D,Rineer J,Vongtama D,et al. Impact of postoperative radiation after esophagectomy for esophageal cancer[J].J Thorac Oncol,2010,5(2):244-250.DOI:10.1097/JTO.0b013e3181c5e34f.
[14] Lee J,Lee KE,Im YH,et al. Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma[J].Ann Thorac Surg,2005,80(4):1170-1175.DOI:10.1016/j.athoracsur.2005.03.058.
[15] Zheng B,Zheng W,Zhu Y,et al. Role of adjuvantchemoradiotherapy in treatment of resectable esophagealcarcinoma:a meta-analysis[J].Chin Med J,2013,126(6):1178-1182.DOI:10.3760/cma.j.issn.0366-6999.20121798.
[16] 曹秀峰,吕进,朱斌,等.局部晚期食管鳞状细胞癌术后放疗和化疗的前瞻性研究[J].中华肿瘤杂志,2010,32(6):452-455.DOI:10.3760/cma.j.issn.0253-3766.2010.06.013.
Cao XF,Lv J,Zhu B,et al. A prospective comparison between surgery alone and postoperative chemoradiotherapy for locally advanced esophageal squamous cell carcinoma[J].Chin J Oncol,2010,32(6):452-455.DOI:10.3760/cma.j.issn.0253-3766.2010.06.013.
[17] 王玉祥,王丽丽,杨琼,等.pT₃N₀M₀期胸段食管鳞癌胸腹两野根治术后的复发模式[J].中华肿瘤杂志,2016,38(1):48-54.DOI:10.3760/cma.j.issn.0253-3766.2016.01.010.
Wang YX,Wang LL,Yang Q,et al. Patterns of recurrence in patients with stage pT₃N₀M₀ horacic esophageal squamous cell carcinoma after two-field esophagectomy[J].Chin J Oncol,2016,38(1):48-54.DOI:10.3760/cma.j.issn.0253-3766.2016.01.010.
[18] Guo XF,Mao T,Gu ZT,et al. Clinical study on postoperative recurrence in patientswith pN₀ esophageal squamous cell carcinoma[J].JCardiothorac Surg,2014,9:150.DOI:10.1186/s13019-014-0150-4.
[19] Eloubeidi MA,Desmond R,Arguedas MR,et al. Prognostic factors for the survival of patients with esophageal carcinoma in the U.S.:the importance of tumor length and lymph node status[J].Cancer,2002,95(7):1434-1443.DOI:10.1002/cncr.10868.
[20] 胡涛,晏大学,熊辉,等.食管癌外科治疗的预后因素分析[J].临床外科杂志,2008,16(3):191-193.DOI:10.3969/j.issn.1005-6483.2008.03.021.
Hu T,Yan DX,Xiong H,et al. Analysis on factors influencing the prognosis of the patients subject to esophagectomy[J].J Clin Surg,2008,16(3):191-193.DOI:10.3969/j.issn.1005-6483.2008.03.021.
[21] Lin CS,Cheng CT,Liu CY,et al. Radical lymph node dissection in primary esophagectomy for esophageal squamous cell carcinoma[J].Ann Thorac Surg,2015,100(1):278-286.DOI:10.1016/j.athoracsur.2015.02.053
[22] Griffiths EA,Brummell Z,Gorthi G,et al. Tumor length as a prognostic factor in esophageal malignancy:univariate and multivariate survival analyses[J].J Surg Oncol,2006,93(4):258-267.DOI:10.1002/jso.20449.